Cellular tools for biosimilar mAb analysis
نویسندگان
چکیده
Background For the development of biosimilar monoclonal antibodies (mAb) or related substances containing the IgG Fc part it is mandatory to fully compare immunological properties between originator and biosimilar in a “comparability exercise” [1]. The most complex Fc associated function to mediate antibody dependent cellular cytotoxicity (ADCC) needs to be characterized using the active substance of the biosimilar and the comparator. From a regulatory point of view potency assays should reflect the proposed mode of action but in vitro ADCC assays are considered difficult to validate due to the variability of the primary effector cells [2,3]. The requirement to test for ADCC with high precision and accuracy is challenging. Design of cell lines to replace primary cells for effector or target cells is a solution to provide tools for standardized and extensive biosimilar testing.
منابع مشابه
Development of antibody arrays for monoclonal antibody Higher Order Structure analysis
Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of the peptides to a carrier protein, KLH. It was shown that good peptide specificity was achieved from the a...
متن کاملWaiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges
Biosimilars are biological medicinal products that contain a version of the active substance of an already authorised original biological medicinal product (the innovator or reference product). The first approved biosimilar medicines were small proteins, and more recently biosimilar versions of innovator monoclonal antibody (mAb) drugs have entered development as patents on these more complex p...
متن کاملBiosimilar Products Scientific Principles , Challenges , and Opportunities
T he Chemistry, Manufacturing, and Controls (CMC) Strategy Forum held on 22 January 2012 in San Francisco, CA, focused on selected scientific and regulatory aspects in the development of biosimilar products. Such products are becoming an increasingly important area of interest for both the biopharmaceutical industry and regulatory agencies. Biosimilars are highly complex, and scientists have be...
متن کاملAdvanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques
In this study, we demonstrate the utility of ultra-performance liquid chromatography coupled to mass spectrometry (MS) and ion-mobility spectrometry (IMS) to characterize and compare reference and biosimilar monoclonal antibodies (mAbs) at an advanced level. Specifically, we focus on infliximab and compared the glycan profiles, higher order structures, and their host cell proteins (HCPs) of the...
متن کاملStructural Comparison of Infliximab and a Biosimilar via Subunit Analysis Using the Waters Biopharmaceutical Platform with UNIFI
K E Y W O R D S Biosimilar, intact mass analysis, intact mass subunit analysis, light chain, heavy chain, glycosylation, glycoprofile, infliximab, mAb, biotherapeutic characterization A P P L I C AT IO N B E N E F I T S A streamlined workflow within an integrated UPLC-MS/MS system solution that features automated data acquisition, processing, and reporting, and that is deployable to both regula...
متن کامل